Clinical Trial

mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In second line with advanced or recurrent biliary tract cancer refractory to first line gemcitabine plus cisplatin,efficacy of mFOLFOX/FOLFIRI vs mFOLFOX will be evaluated at randomized phase 2 trial.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-15
notable Trial sites expanded: 1 -> 11 locations 2026-08-15
Trial Details
NCT Number NCT07062536
Lead Sponsor Seoul National University Bundang Hospital
Conditions Biliary Cancer Metastatic
Enrollment 130 participants
Start Date 2025-08-27
Primary Completion 2027-04-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-14